RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

July 6, 2026 - 20:52

ALISO VIEJO, Calif. - RxSight, Inc. has released select preliminary financial figures for the second quarter of 2026, along with updates on its product development pipeline. The announcement follows the company's recent strategic collaboration with Alcon, which focuses on developing and commercializing light-adjustable intraocular lenses designed to correct presbyopia.

For the second quarter, RxSight expects total company revenue to land between $32 million and $34 million. This early look at the numbers comes as the company shifts its focus following the Alcon partnership. The collaboration is expected to expand the reach of RxSight's light-adjustable lens technology into the presbyopia-correcting market, a significant step beyond its current offerings.

The company also provided updates on its standalone product pipeline. While specific details on upcoming products were limited, RxSight indicated that development efforts are continuing in parallel with the Alcon agreement. The goal is to maintain momentum in its core light-adjustable lens platform while leveraging the partnership to enter new segments of the cataract and refractive surgery market.

Management noted that these preliminary results are subject to final review and could change. The company plans to release full second-quarter financial results in the coming weeks. Investors are watching closely to see how the Alcon deal will impact revenue growth and product timelines moving forward.